medalist: luspatercept and erythropoiesis biomarkers in mds
Published 3 years ago • 137 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:12
medalist: os & risk of disease progression in patients with mds treated with luspatercept
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
3:54
results of medalist: luspatercept reduces transfusion burden in mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
13:02
introduction to hematology |medical laboratory science
-
2:49
robarts virtual tour - molecular pathology
-
13:13
precision medicine in myeloproliferative neoplasms
-
1:44
medalist: episodes of transfusion independence in patients with lr-mds treated with luspatercept
-
1:31
overall survival of patients following treatment with luspatercept in the medalist trial
-
7:05
state-of-the-art treatment regimens for lr-mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
1:49
evaluating erythroid precursors in patients with lr-mds to predict response to esas
-
1:17
phase ii study of tosedostat in mds
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml